Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$312.32 +1.2%	$276.19	$153.23 ▼ $317.54	$40.72B	0.22	932,639 shs	981,185 shs
BIIB Biogen	$126.54 0.0%	$124.59	$110.04 ▼ $238.00	$18.54B	0.14	1.43 million shs	2.33 million shs
EXEL Exelixis	$40.74 -1.5%	$40.20	$21.36 ▼ $48.85	$11.11B	0.28	2.37 million shs	2.70 million shs
INCY Incyte	$68.27 -0.8%	$63.24	$53.56 ▼ $83.95	$13.22B	0.67	2.05 million shs	1.74 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+2.51%	+7.08%	+10.23%	+102.99%
BIIB Biogen	0.00%	-4.36%	-3.07%	-10.19%	-43.42%
EXEL Exelixis	0.00%	-2.49%	-8.16%	+10.23%	+88.96%
INCY Incyte	0.00%	-1.37%	+4.55%	+10.26%	+11.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.0755 of 5 stars	2.4	5.0	4.3	2.1	2.5	0.6
BIIB Biogen	4.7895 of 5 stars	4.2	3.0	3.7	2.6	1.7	2.5
EXEL Exelixis	4.6205 of 5 stars	2.2	2.0	4.3	2.2	2.5	4.4
INCY Incyte	4.4885 of 5 stars	2.1	4.0	3.1	3.1	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	2.33% Upside
BIIB Biogen	2.38	Hold	$188.19	48.72% Upside
EXEL Exelixis	2.47	Hold	$39.76	-2.39% Downside
INCY Incyte	2.22	Hold	$74.53	9.17% Upside

Current Analyst Ratings Breakdown

Latest EXEL, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	EXEL Exelixis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $47.00
6/5/2025	EXEL Exelixis	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $46.00
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$61.00
5/27/2025	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$72.00 ➝ $73.00
5/15/2025	EXEL Exelixis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$45.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.11	N/A	N/A	$0.52 per share	600.62
BIIB Biogen	$9.68B	1.92	$23.09 per share	5.48	$114.71 per share	1.10
EXEL Exelixis	$2.17B	5.12	$1.93 per share	21.15	$7.86 per share	5.18
INCY Incyte	$4.24B	3.12	$0.55 per share	123.32	$17.90 per share	3.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	350.92	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.49	7.66	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
EXEL Exelixis	$521.27M	$2.20	18.52	15.98	0.83	27.99%	28.81%	21.94%	8/5/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.35	10.44	0.57	0.48%	2.77%	1.77%	7/29/2025 (Estimated)

Latest EXEL, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BIIB Biogen	0.27	1.44	1.01
EXEL Exelixis	N/A	3.50	3.44
INCY Incyte	0.01	2.04	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
EXEL Exelixis	85.27%
INCY Incyte	96.97%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.18%
EXEL Exelixis	2.82%
INCY Incyte	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
EXEL Exelixis	1,147	272.71 million	265.02 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable

EXEL, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

June 19 at 12:15 PM | zacks.com

FDA approves Monjuvi for relapsed or refractory FL

June 19 at 10:44 AM | thepharmaletter.com

Tafasitamab Combo Approved for r/r Follicular Lymphoma

June 19 at 5:42 AM | medscape.com

CWA Asset Management Group LLC Purchases 29,397 Shares of Incyte Corporation (NASDAQ:INCY)

June 19 at 5:15 AM | marketbeat.com

Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC

June 19 at 3:53 AM | marketbeat.com

Incyte Lymphoma Treatment Gets FDA Approval

June 18 at 5:01 PM | marketwatch.com

Incyte granted FDA label expansion for lymphoma therapy Monjuvi

June 18 at 4:07 PM | seekingalpha.com

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

June 18 at 3:39 PM | businesswire.com

Mn Services Vermogensbeheer B.V. Boosts Stake in Incyte Corporation (NASDAQ:INCY)

June 18 at 4:06 AM | marketbeat.com

Stifel Nicolaus Upgrades Incyte (NASDAQ:INCY) to "Buy"

June 18 at 1:23 AM | americanbankingnews.com

Incyte (INCY) Receives a Buy from Oppenheimer

June 17 at 11:29 PM | theglobeandmail.com

Incyte (INCY) Receives a Buy from TD Cowen

June 17 at 11:29 PM | theglobeandmail.com

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

June 17 at 1:10 PM | zacks.com

Positive Buy Rating for Incyte Driven by Promising INCA33989 Trial Results and Favorable Safety Profile

June 17 at 2:49 AM | tipranks.com

Incyte (INCY) Surges on Promising Blood Disorder Treatment Results

June 16, 2025 | gurufocus.com

Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | INCY Stock News

June 16, 2025 | gurufocus.com

Incyte (NASDAQ:INCY) Shares Gap Up - What's Next?

June 16, 2025 | marketbeat.com

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

June 16, 2025 | benzinga.com

Stock Movers: T-Mobile, MGM, Incyte

June 16, 2025 | bloomberg.com

Incyte (NASDAQ:INCY) Upgraded by Stifel Nicolaus to Buy Rating

June 16, 2025 | marketbeat.com

Shikiar Asset Management Inc. Has $8.38 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

June 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Best Utilities Stocks for Stability and Growth in 2025
By Chris Markoch | May 21, 2025
View Best Utilities Stocks for Stability and Growth in 2025

EXEL, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$312.32 +3.61 (+1.17%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$310.83 -1.49 (-0.48%)

As of 06/18/2025 04:55 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$126.54 -0.02 (-0.02%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$126.50 -0.04 (-0.03%)

As of 06/18/2025 07:11 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Exelixis NASDAQ:EXEL

$40.74 -0.61 (-1.48%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$40.70 -0.04 (-0.10%)

As of 06/18/2025 07:37 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Incyte NASDAQ:INCY

$68.27 -0.54 (-0.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$67.68 -0.58 (-0.86%)

As of 06/18/2025 07:11 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time